Surgery – Respiratory method or device – Means for mixing treating agent with respiratory gas
Reexamination Certificate
2001-09-20
2004-02-24
Lewis, Aaron J. (Department: 3761)
Surgery
Respiratory method or device
Means for mixing treating agent with respiratory gas
C128S203270, C128S204170, C219S538000, C338S280000
Reexamination Certificate
active
06694975
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to portable devices and methods useful for optimizing the diameter distribution of a medical aerosol, and reducing the amount of variability arising from variations in ambient conditions. More specifically, this invention relates to portable devices for controlling the temperature of air to be mixed with aerosol particles of drugs to be delivered to the lung.
BACKGROUND OF THE INVENTION
There are several known methods for the aerosolized delivery of drugs. In general, the methods include: (1) placing an aqueous formulation within a nebulizer device which by various mechanical means causes the drug formulation to be aerosolized in a continuous stream which is inhaled by the patient; (2) dry powder inhalers which create a fine powder of the drug and aerosolize the powder in a dust form which is inhaled; (3) metered dose inhalers which dissolve or disperse the drug in a low boiling point propellant; and (4) more current devices such as that disclosed within U.S. Pat. No. 5,660,166 issued Aug. 26, 1997 which force aqueous formulations through a nozzle to create an aerosol which is inhaled by the patient.
In accordance with each of the known methods for aerosolizing a drug it is important to produce an aerosol which has particles within a desired diameter range, e.g. 0.5 to 12.0 microns and more preferably 1.0 to 3.5 microns. In addition to producing small particles it is preferable to produce particles which are relatively consistent in diameter, i.e. produce an aerosol wherein a large percentage of the particles fall within the desired diameter range. In addition, it is desirable to produce an aerosol which has the property that the key measures of aerosol quality, such as particle diameter and dose emitted are not effected by ambient conditions such as temperature and or relative humidity. With any of the known methods for aerosol delivery of drugs there are difficulties with respect to making the particles sufficiently small. Along with these difficulties there are difficulties with respect to creating particles which are relatively consistent in diameter. These difficulties are particularly acute when attempting to provide for systemic delivery of an aerosolized drug. Efficient systemic delivery requires that the aerosol be delivered deeply into the lung so that the drug can efficiently reach the air/blood exchange membranes in the lung and migrate into the circulatory system.
Aerosol delivery to the lungs has been used for delivery of medication for local therapy (Graeser and Rowe,
Journal of Allergy
6:415 1935). The large surface area, thin epithelial layer, and highly vascularized nature of the peripheral lung (Taylor,
Adv. Drug Deliv. Rev
. 5:37 1990) also make it an attractive site for non-invasive systemic delivery. Unlike other avenues of non-invasive delivery such as trans-dermal, nasal, or buccal, the lung is designed as a portal of entry to the systemic circulation. However, targeting the peripheral lung requires careful control of the aerosol particle diameter and velocity distributions, in order to by pass the exquisitely evolved particle filtering and clearing functions of the bronchial airways.
Many authors have reported results of experiments or mathematical models showing that micron sized particles are required for delivery to the lungs (c.f. Stahlhofen, Gebhart and Heyder,
Am. Ind. Hyg. Assoc. J
. 41:385 1980, or Ferron, Kreyling and Haider,
J. Aerosol Sci
. 19:611 1987). One example is the model of the Task Group on Lung Dynamics (Morrow et. al.
Health Physics
12:173 1966). As
FIG. 1
shows, under the assumptions of this model, particles of diameter less than ~3.5 &mgr;m are required to avoid the oropharynx and bronchial airways.
FIG. 1
might suggest that the maximum efficiency of deposition of drugs delivered to the pulmonary region of the lung is limited to ~60%. However, as can be seen in
FIG. 2
, efficiencies approaching 100% can be achieved by allowing the particles to settle gravitationally during a ten second breath hold (Byron,
J. Pharm. Sci
. 75:433 1986).
It has been demonstrated that ambient conditions can strongly effect the amount of aerosol particles less than 3.5 &mgr;m emitted from aerosol generation device. One example is the work of Phipps and Gonda (
Chest
97:1327-1332, 1990) showing that the amount of aerosol less than 3.5 &mgr;m delivered by an aerosol drug delivery device changed from 33% to 73% when the relative humidity changed from 100% to 70%. Similar work with a dry powder (Hickey et al
J. Pharm. Sci
. 79, 1009-1011) demonstrated a change in the amount of aerosol less than 3.5 &mgr;m from 9% to 42% when the ambient relative humidity changed from 97% to 20%. These data are tabulated in Table 1.
TABLE 1
Effect of RH on Particle Diameter Distribution
Aerosol
T, ° C.
R. H., %
% <3.5 &mgr;m
Isotonic Saline
1
, Hudson Up-Draft
23-24°
100%
33%
Isotonic Saline
1
, Hudson Up-Draft
23-24°
65-75%
73%
Fluorescein Powder
2
37 ± 0.1°
97 ± 1%
9%
Fluorescein Powder
2
37 ± 0.1°
20 ± 5%
42%
1
Phipps and Gonda, 1990
2
Hickey et al 1990
A device useful for controlling the temperature of the air surrounding an aerosolized drug formulation is provided in U.S. Pat. No. 6,131,570, which issued on Oct. 17, 2000. An element is preheated prior to aerosolizing the drug formulation. After preheating has been accomplished, the drug formulation is aerosolized substantially contemporaneously with the control of air flow through a space in which the preheated element is contained, whereby heated air mixes with the aerosolized drug formulation, thereby evaporating liquid carrier from the aerosol particles to obtain smaller particles to be delivered to the lungs of the patient.
Since devices of this type are designed to be portable, primary goals include making the heating element as efficient as possible for performing the functions of rapidly heating up and storing energy during the preheat stage, as well as rapidly releasing heat to the air as it flows by the heating element to be delivered to the aerosolized drug. Efficient storing and releasing of heat energy are basically contradictory in nature, however, and these goals remain a problem to be addressed, since increasing the efficiency of these features allows a reduction in the size and weight of the power source which must necessarily be included in a portable device.
Many pharmaceutical compounds of a wide range of molecular weights are potential candidates for systemic delivery via the lung. Small molecules analgesics such as morphine or fentanyl could be delivered to pain patients, e.g. cancer or post-operative patients. Morphine has demonstrated bioavailability when delivered via the lung (S. J. Farr, J. A. Schuster, P. M. Lloyd, L. J. Lloyd, J. K. Okikawa, and R. M. Rubsamen. In R. N. Dalby, P. R. Byron, and S. J. Farr (eds.),
Respiratory Drug Delivery V
, Interpharm Press, Inc., Buffalo Grove, 1996, 175-185).
Potent peptide hormones are available for a variety of therapeutic indications. Leuprolide, for example, is a GnRH super-agonist useful in the treatment of endometriosis and prostate cancer. Leuprolide also has potential applications in the field of breast cancer management and the treatment of precocious puberty. Calcitonin enhances metabolism and may be a useful therapeutic agent for the management of osteoporosis, a common complication of aging.
To treat conditions or diseases of the endocrine system, pharmaceutical formulations containing potent peptide hormones are typically administered by injection. Because the stomach presents a highly acidic environment, oral preparations of peptides are unstable and readily hydrolyzed in the gastric environment. Currently, there are no oral preparations of therapeutic peptide agents commercially available.
Both calcitonin and leuprolide can be administered nasally. (See Rizzato et al.,
Curr. Ther. Res
. 45:761-766, 1989.) Both drugs achieve blood levels when introduced into the nose from an aerosol spray device. However, experiments by Adjei et
Eliahu Avi
Flaim Christopher J.
Rosell Joan
Schuster Jeffrey A.
Aradigm Corporation
Bozicevic Field & Francis LLP
LaSalle Carol M.
Lewis Aaron J.
LandOfFree
Temperature controlling device for aerosol drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Temperature controlling device for aerosol drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Temperature controlling device for aerosol drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3301025